Department of Paediatrics and Paediatric Infectious Diseases, National Institute of Blood Diseases and Bone Marrow Transplant, Karachi 75300, Pakistan.
Department of Microbiology, National Institute of Blood Diseases and Bone Marrow Transplant, Karachi 75300, Pakistan.
J Public Health (Oxf). 2021 Apr 12;43(1):3-8. doi: 10.1093/pubmed/fdaa170.
The recent pandemic by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a global emergency. There is large number of asymptomatic cases of SARS-CoV-2 that are not reported. Hence, serological evidence of SARS-CoV2 antibodies is warranted for a better estimation of the actual number of infected patients to limit the disease spread and to get an idea of herd immunity.
This is a cross-sectional study conducted from May 2020 to July 2020 at National Institute of Blood Diseases at Pakistan. The study includes healthcare workers (HCWs), community and industrial workers. The anti-SARS-CoV-2 test was performed by electrochemiluminescence immunoassay analyzer.
A total of 1675 samples have been received from three groups of population. The percentage positivity for industrial employees is high (50.3%) for HCW (13.2%) and community population (34%).Total percentage for positive antibodies result is ~36%.
Our seroprevalence is 36%, which still far from herd immunity that needs to be at least 60-70% in population. If we consider acquiring 60% seroprevalence in next few months, then herd immunity is not far from reality, provided the antibodies did not decline with time. Although the current study is based on a small sample of participants, the findings suggest a study with larger population to implement stronger and targeted interventions.
由严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）引起的最近的大流行是全球性的紧急情况。有大量未报告的 SARS-CoV-2 无症状病例。因此，有必要进行 SARS-CoV-2 抗体血清学证据，以更好地估计实际感染患者的数量，以限制疾病的传播，并了解群体免疫情况。
这是 2020 年 5 月至 2020 年 7 月在巴基斯坦国家血液疾病研究所进行的一项横断面研究。该研究包括医护人员（HCWs）、社区和工业工人。采用电化学发光免疫分析仪进行抗 SARS-CoV-2 检测。
共收到来自三组人群的 1675 份样本。工业员工的阳性率最高（50.3%），HCW（13.2%）和社区人群（34%）。总阳性抗体结果百分比约为 36%。
我们的血清流行率为 36%，这仍远低于群体免疫，群体免疫需要至少达到 60-70%的人口。如果我们考虑在未来几个月内获得 60%的血清流行率，那么群体免疫就不再遥不可及，前提是抗体不会随时间下降。尽管目前的研究基于小样本参与者，但研究结果表明，需要进行更大人群的研究，以实施更强有力和有针对性的干预措施。
